Long-term response of more than 9 years to regorafenib in a heavily pretreated patient with metastatic colorectal cancer.
Journal
Anti-cancer drugs
ISSN: 1473-5741
Titre abrégé: Anticancer Drugs
Pays: England
ID NLM: 9100823
Informations de publication
Date de publication:
01 03 2023
01 03 2023
Historique:
pubmed:
3
2
2023
medline:
10
2
2023
entrez:
2
2
2023
Statut:
ppublish
Résumé
Colorectal cancer (CRC) is the third most common cancer worldwide, with approximately 1.9 million new diagnoses and 935 000 deaths annually. Overall, there is accumulating evidence that receiving all available treatments leads to a survival advantage and, although tailored treatments might be appropriate for selected patients, the one-size-fits-all approach is still widely used in chemo-refractory patients. Currently, different antiangiogenics and multitarget agents are indicated in treatment of metastatic CRC (mCRC) whereas the identification of useful predictive factors for the treatment response is lacking. Analysis of potential predictive biomarkers of efficacy of regorafenib is still ongoing but may prove to be difficult because of its nonspecific activity across a wide range of angiogenic, oncogenic, stromal, and intracellular signaling kinases. We present a case of a 57-year-old Caucasian woman diagnosed with recurrence after curative surgery for rectal adenocarcinoma stage III (ypT3N2). Despite undergoing multiple lines of standard chemotherapy, disease control could not be maintained. Consequently, regorafenib, a multikinase inhibitor with antiangiogenic proprieties, was started as a late-line treatment and a dose reduction strategy allowed a long-term response of more than 9 years with good tolerability.
Identifiants
pubmed: 36730636
doi: 10.1097/CAD.0000000000001410
pii: 00001813-202303000-00013
doi:
Substances chimiques
regorafenib
24T2A1DOYB
Phenylurea Compounds
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
451-454Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Araghi M, Soerjomataram I, Bardot A, Ferlay J, Cabasag CJ, Morrison DS, et al. Changes in colorectal cancer incidence in seven high-income countries: a population-based study. Lancet Gastroenterol Hepatol 2019; 4:511–518.
Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen Y-J, Ciombor KK, et al. Colon cancer, version 2.2021, NCCN clinical practice guidelines in Oncology. J Natl Compr Canc Netw 2021; 19:329–359.
Antonuzzo L, Giommoni E, Pastorelli D, Latiano T, Pavese I, Azzarello D, et al. Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: the OBELIX study. World J Gastroenterol 2015; 21:7281–7288.
Borelli B, Moretto R, Lonardi S, Bonetti A, Antoniotti C, Pietrantonio F, et al. TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer. ESMO Open 2018; 3:e000403.
Damato A, Bergamo F, Antonuzzo L, Nasti G, Iachetta F, Romagnani A, et al. FOLFOXIRI/bevacizumab plus nivolumab as first-line treatment in metastatic colorectal cancer RAS/BRAF mutated: safety run-in of phase II NIVACOR trial. Front Oncol 2021; 11:766500.
Lavacchi D, Roviello G, Giommoni E, Dreoni L, Derio S, Brugia M, et al. Aflibercept plus FOLFIRI as second-line treatment for metastatic colorectal cancer: a single-institution real-life experience. Cancer 2021; 13:3863.
Pinto C, Antonuzzo L, Porcu L, Aprile G, Maiello E, Masi G, et al. Efficacy and safety of Bevacizumab combined with Fluoropyrimidine monotherapy for unfit or older patients with metastatic colorectal cancer: a systematic review and meta-analysis. Clin Colorectal Cancer 2017; 16:e61–e72.
Danesi R, Fogli S, Indraccolo S, Del Re M, Dei Tos AP, Leoncini L, et al. Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of molecular tumor boards. ESMO Open 2021; 6:100040.
Fanotto V, Ongaro E, Rihawi K, Avallone A, Silvestris N, Fornaro L, et al. HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives. Oncotarget 2016; 7:69060–69074.
Lavacchi D, Roviello G, D’Angelo A. Tumor-agnostic treatment for cancer: when how is better than where. Clin Drug Investig 2020; 40:519–527.
Loupakis F, Antonuzzo L, Bachet J-B, Kuan F-C, Macarulla T, Pietrantonio F, et al. Practical considerations in the use of regorafenib in metastatic colorectal cancer. Ther Adv Med Oncol 2020; 12:1758835920956862.
Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 2015; 372:1909–1919.
Morano F, Raimondi A, Pagani F, Lonardi S, Salvatore L, Cremolini C, et al. Temozolomide followed by combination with low-dose Ipilimumab and Nivolumab in patients with microsatellite-stable, O6-methylguanine–DNA methyltransferase–silenced metastatic colorectal cancer: the MAYA trial. J Clin Oncol 2022; 40:1562–1573.
Grothey A, Cutsem EV, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381:303–312.
Bekaii-Saab TS, Ou F-S, Ahn DH, Boland PM, Ciombor KK, Heying EN, et al. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncol 2019; 20:1070–1082.
Antonuzzo L., Lunghi A., Giommoni E., Brugia M., Di Costanzo F. Regorafenib also can cause osteonecrosis of the jaw. JNCI: J Natl Cancer Inst 2016; 108:djw002.
Antonuzzo L, Lunghi A, Petreni P, Brugia M, Laffi A, Giommoni E, et al. Osteonecrosis of the jaw and angiogenesis inhibitors: a revival of a rare but serious side effect. Curr Med Chem 2017; 24:3068–3076.
Liu Y, Lyu J, Burdett KB, Sibley AB, Hatch AJ, Starr MD, et al. Prognostic and predictive biomarkers in patients with metastatic colorectal cancer receiving regorafenib. Mol Cancer Ther 2020; 19:2146–2154.
Inghilesi AL, Gallori D, Antonuzzo L, Forte P, Tomcikova D, Arena U, et al. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib. World J Gastroenterol 2014; 20:786–794.
Marmorino F, Salvatore L, Barbara C, Allegrini G, Antonuzzo L, Masi G, et al. Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer. Br J Cancer 2017; 116:318–323.
Iorio J, Lastraioli E, Tofani L, Petroni G, Antonuzzo L, Messerini L, et al. hERG1 and HIF-2α behave as biomarkers of positive response to bevacizumab in metastatic colorectal cancer patients. Transl Oncol 2020; 13:100740.
Callebout E, Ribeiro SM, Laurent S, De Man M, Ferdinande L, Claes KBM, et al. Long term response on regorafenib in non-V600E BRAF mutated colon cancer: a case report. BMC Cancer 2019; 19:567.
Antoniotti C, Marmorino F, Boccaccino A, Martini S, Antista M, Rossini D, et al. Early modulation of angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer. Eur J Cancer 2022; 165:116–124.
Rosati G, Del Gaudio N, Scarano E, Cifarelli RA, Altucci L, Bilancia D. Unexpected and durable response with regorafenib in a metastatic colorectal cancer patient without KDR mutation. Medicine (Baltimore) 2018; 97:e11178.
Martinelli E, Sforza V, Cardone C, Capasso A, Nappi A, Martini G, et al. Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment. ESMO Open 2017; 2:e000177.
Lastraioli E, Antonuzzo L, Fantechi B, Di Cerbo L, Di Costanzo A, Lavacchi D, et al. KRAS and NRAS mutation detection in circulating DNA from patients with metastatic colorectal cancer using BEAMing assay: concordance with standard biopsy and clinical evaluation. Oncol Lett 2021; 21:15.
Roviello G, Lavacchi D, Antonuzzo L, Catalano M, Mini E. Liquid biopsy in colorectal cancer: no longer young, but not yet old. World J Gastroenterol 2022; 28:1503–1507.
Lastraioli E, Lavacchi D, Palmieri VE, Castiglione F, Messerini L, Di Costanzo F, et al. Evaluation of RAS mutational status through BEAMing assay to monitor disease progression of metastatic colorectal cancer: a case report. Anticancer Drug 2020; 31:979–982.
Rachiglio AM, Forgione L, Pasquale R, Barone CA, Maiello E, Antonuzzo L, et al. Dynamics of RAS/BRAF mutations in cfDNA from metastatic colorectal carcinoma patients treated with polychemotherapy and anti-EGFR monoclonal antibodies. Cancer 2022; 14:1052.
Salvianti F, Gelmini S, Mancini I, Pazzagli M, Pillozzi S, Giommoni E, et al. Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study. Br J Cancer 2021; 125:94–100.
Yoshino K, Manaka D, Kudo R, Kanai S, Mitsuoka E, Kanto S, et al. Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report. J Med Case Rep 2017; 11:227.
Baik H, Lee HJ, Park J, Park HY, Park J, Lee S, et al. Complete response of MSI-high metastatic colon cancer following treatment with regorafenib: a case report. Mol Clin Oncol 2021; 15:243.
Tang R, Kain T, Herman J, Seery T. Durable response using regorafenib in an elderly patient with metastatic colorectal cancer: case report. Cancer Manag Res 2015; 7:357–360.
Tashiro K, Shinto E, Kajiwara Y, Mochizuki S, Okamoto K, Nishizawa A, et al. Systemic steroid treatment can desensitize the skin reaction due to regorafenib in a recurrence colorectal cancer patient. Int Cancer Conf J 2019; 8:164–169.
Roberto M, Falcone R, Mazzuca F, Archibugi L, Castaldi N, Botticelli A, et al. The role of stereotactic body radiation therapy in oligometastatic colorectal cancer. Medicine (Baltimore) 2017; 96:e9023.